{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:02:31Z","timestamp":1778832151214,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T00:00:00Z","timestamp":1386201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10549-013-2792-7","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T19:41:36Z","timestamp":1386186096000},"page":"159-169","source":"Crossref","is-referenced-by-count":39,"title":["Symptoms of endocrine treatment and outcome in the BIG 1-98 study"],"prefix":"10.1007","volume":"143","author":[{"name":"for the BIG 1-98 Collaborative and International Breast Cancer Study Groups","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Huober","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. F.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rabaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"L\u00e1ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wardley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,5]]},"reference":[{"key":"2792_CR1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771\u2013784","journal-title":"Lancet"},{"key":"2792_CR2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","volume":"12","author":"MM Regan","year":"2011","unstructured":"Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71\u00a0years median follow-up. Lancet Oncol 12:1101\u20131108","journal-title":"Lancet Oncol"},{"key":"2792_CR3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141","journal-title":"Lancet Oncol"},{"key":"2792_CR4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"key":"2792_CR5","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/en.142.11.4589","volume":"142","author":"ER Simpson","year":"2001","unstructured":"Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142:4589\u20134594","journal-title":"Endocrinology"},{"key":"2792_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr2818","volume":"13","author":"S Gaillard","year":"2011","unstructured":"Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205","journal-title":"Breast Cancer Res"},{"key":"2792_CR7","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758\u20131764","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61\u201374","journal-title":"Clin Pharmacol Ther"},{"key":"2792_CR10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299\u20131309","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936\u2013942","journal-title":"J Clin Oncol"},{"key":"2792_CR12","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Per\u00e9z-Soler","year":"2005","unstructured":"Per\u00e9z-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"key":"2792_CR13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","volume":"11","author":"AM Jubb","year":"2010","unstructured":"Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172\u20131183","journal-title":"Lancet Oncol"},{"key":"2792_CR14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"11","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 11:710\u2013719","journal-title":"J Clin Oncol"},{"key":"2792_CR15","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1002\/sim.738","volume":"20","author":"A Agresti","year":"2001","unstructured":"Agresti A (2001) Exact inference for categorical data: recent advances and continuing controversies. Stat Med 20:2709\u20132722","journal-title":"Stat Med"},{"key":"2792_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"2792_CR17","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50:163\u2013170","journal-title":"Cancer Chemotherapy Reports"},{"key":"2792_CR18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"2792_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187\u2013220","journal-title":"J R Stat Soc B"},{"key":"2792_CR20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"2792_CR21","first-page":"147","volume-title":"Counting processes and survival analysis","author":"TR Fleming","year":"1991","unstructured":"Fleming TR, Harrington DP (1991) Counting processes and survival analysis. Wiley, New York, pp 147\u2013148"},{"key":"2792_CR22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143\u20131148","journal-title":"Lancet Oncol"},{"key":"2792_CR23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ Velde van de","year":"2011","unstructured":"van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321\u2013331","journal-title":"Lancet"},{"key":"2792_CR24","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1093\/annonc\/mds055","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Kieback DG, Tams J et al (2012) Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 23:2566\u20132572","journal-title":"Ann Oncol"},{"key":"2792_CR25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.2012.45.3068","volume":"31","author":"DB Fontein","year":"2013","unstructured":"Fontein DB, Seynaeve C, Hadji P et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257\u20132264","journal-title":"J Clin Oncol"},{"issue":"31","key":"2792_CR26","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"V Stearns","year":"2011","unstructured":"Stearns V, Chapman JW, Ma CX et al (2011) Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 29(31):4189\u20134198","journal-title":"J Clin Oncol"},{"issue":"20","key":"2792_CR27","first-page":"1489","volume":"69","author":"V Stearns","year":"2009","unstructured":"Stearns V, Chapman JA, Ma C et al (2009) Treatment emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA 27. Adjuvant aromatase inhibitor trial. Cancer Res 69(20):1489\u20131498","journal-title":"Cancer Res"},{"key":"2792_CR28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(11)70328-X","volume":"13","author":"JSD Mieog","year":"2012","unstructured":"Mieog JSD, Morden JP, Bliss JM et al (2012) Carpal tunnel symptoms and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2\u20133\u00a0years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13:420\u2013432","journal-title":"Lancet Oncol"},{"key":"2792_CR29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00280-011-1615-y","volume":"68","author":"IH Park","year":"2011","unstructured":"Park IH, Lee YS, Lee KS et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 68:1263\u20131271","journal-title":"Cancer Chemother Pharmacol"},{"key":"2792_CR30","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr2813","volume":"13","author":"JJ Mao","year":"2011","unstructured":"Mao JJ, Su HI, Feng R et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8","journal-title":"Breast Cancer Res"},{"key":"2792_CR31","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1200\/JCO.2010.28.5064","volume":"28","author":"JN Ingle","year":"2010","unstructured":"Ingle JN, Schaid DJ, Goss PE (2010) Genome-wide association and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674\u20134682","journal-title":"J Clin Oncol"},{"key":"2792_CR32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA et al (2008) Tamoxifen, hot flashes and breast cancer recurrence. Breast Cancer Res and Treat 108:421\u2013426","journal-title":"Breast Cancer Res and Treat"},{"key":"2792_CR33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:441\u2013451","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452\u2013460","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR35","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","volume":"101","author":"E Basch","year":"2009","unstructured":"Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624\u20131632","journal-title":"J Natl Cancer Inst"},{"key":"2792_CR36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903\u2013909","journal-title":"Lancet Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2792-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2792-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:36:33Z","timestamp":1716244593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2792-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,5]]}}}